These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 9410329)
1. [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers]. Villers A; Soulié M; Haillot O; Boccon-Gibod L Prog Urol; 1997 Sep; 7(4):655-61. PubMed ID: 9410329 [TBL] [Abstract][Full Text] [Related]
2. [Diagnosis of cancer of the prostate (I): Advancements in knowledge and practice since the consensus conference of 1989. The "Cancer of the Prostate" subcommittee of the Committee of Oncology of the French Association of Urology]. Villers A; Grosclaude P; Haillot O; Abbou CC; Richard F; Boccon-Gibod L Prog Urol; 1997 Jun; 7(3):508-15. PubMed ID: 9273082 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
4. [Adenocarcinoma of the prostate]. Dvorácek J Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. Konety BR; Bird VY; Deorah S; Dahmoush L J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287 [TBL] [Abstract][Full Text] [Related]
7. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175 [TBL] [Abstract][Full Text] [Related]
8. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824 [TBL] [Abstract][Full Text] [Related]
9. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909 [TBL] [Abstract][Full Text] [Related]
10. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Postma R; Roobol M; Schröder FH; van der Kwast TH Cancer; 2004 Mar; 100(5):968-75. PubMed ID: 14983492 [TBL] [Abstract][Full Text] [Related]
11. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432 [TBL] [Abstract][Full Text] [Related]
17. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis. Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445 [TBL] [Abstract][Full Text] [Related]
18. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day). Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579 [TBL] [Abstract][Full Text] [Related]
20. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Roobol MJ; Roobol DW; Schröder FH Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]